

Ronald B Goldberg

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7623702/ronald-b-goldberg-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

8,661
citations

31
h-index

85
g-index

85
ext. papers

9,935
ext. citations

8
avg, IF

5.88
L-index

#	Paper	IF	Citations
76	Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 819-836	15.1	3
75	Obesity, Galectin-3, and Incident Heart Failure: The ARIC Study.. <i>Journal of the American Heart Association</i> , 2022 , 11, e023238	6	0
74	Predictive utilities of lipid traits, lipoprotein subfractions and other risk factors for incident diabetes: a machine learning approach in the Diabetes Prevention Program. <i>BMJ Open Diabetes Research and Care</i> , 2021 , 9,	4.5	2
73	Hepatic Fat in Participants With and Without Incident Diabetes in the Diabetes Prevention Program Outcome Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e4746-e4765	5.6	0
72	Sedentary behavior moderates the relationship between physical activity and cardiometabolic risk in young Latino children. <i>Translational Behavioral Medicine</i> , 2021 , 11, 1517-1526	3.2	
71	Daniel H. Mintz (1930-2020): An Extraordinary Physician-Scientist and a Pioneer in Islet Transplantation. <i>Diabetes Care</i> , 2021 , 44, 1727-1733	14.6	
70	The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. <i>Journal of Clinical Lipidology</i> , 2021 , 15, 33-60	4.9	33
69	Duration of Diabetes and Incident Heart Failure: The ARIC (Atherosclerosis Risk In Communities) Study. <i>JACC: Heart Failure</i> , 2021 , 9, 594-603	7.9	5
68	Clinical Approach to Assessment and Amelioration of Atherosclerotic Vascular Disease in Diabetes. <i>Frontiers in Cardiovascular Medicine</i> , 2020 , 7, 582826	5.4	2
67	Defining Abdominal Obesity as a Risk Factor for Coronary Heart Disease in the U.S.: Results From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). <i>Diabetes Care</i> , 2020 , 43, 1774-1780	14.6	4
66	The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol in Diabetes. <i>Diabetes Care</i> , 2020 , 43, 1673-1678	14.6	14
65	A Comprehensive Update on the Chylomicronemia Syndrome. <i>Frontiers in Endocrinology</i> , 2020 , 11, 5939317	3.17	19
64	Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. <i>Diabetes Care</i> , 2019 , 42, 601-608	14.6	53
63	Does diabetes prevention translate into reduced long-term vascular complications of diabetes?. <i>Diabetologia</i> , 2019 , 62, 1319-1328	10.3	24
62	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019 , 139, e1082-e1143	16.7	836
61	Non-traditional biomarkers and incident diabetes in the Diabetes Prevention Program: comparative effects of lifestyle and metformin interventions. <i>Diabetologia</i> , 2019 , 62, 58-69	10.3	16
60	Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 486-496	5.6	4

59	Response to Letter to the Editor: "Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 2068	5.6	
58	Associations of hyperglycemia and insulin resistance with biomarkers of endothelial dysfunction in Hispanic/Latino youths: Results from the Hispanic Community Children's Health Study/Study of Latino Youth (SOL Youth). <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 836-842	3.2	5
57	Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium. <i>Circulation</i> , 2017 , 136, 52-64	16.7	68
56	A Shift in ApoM/S1P Between HDL-Particles in Women With Type 1 Diabetes Mellitus Is Associated With Impaired Anti-Inflammatory Effects of the ApoM/S1P Complex. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017 , 37, 1194-1205	9.4	33
55	Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. <i>BMJ Open Diabetes Research and Care</i> , 2017 , 5, e000438	4.5	57
54	New JAG1 Mutation Causing Alagille Syndrome Presenting With Severe Hypercholesterolemia: Case Report With Emphasis on Genetics and Lipid Abnormalities. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 350-353	5.6	12
53	Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. <i>American Journal of Medicine</i> , 2016 , 129, 753.e13-22	2.4	14
52	Accelerated atherosclerosis and elevated lipoprotein (a) after liver transplantation. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 434-7	4.9	2
51	Lipoprotein composition in patients with type 1 diabetes mellitus: Impact of lipases and adipokines. <i>Journal of Diabetes and Its Complications</i> , 2016 , 30, 657-68	3.2	5
50	Comprehensive Analysis of Established Dyslipidemia-Associated Loci in the Diabetes Prevention Program. <i>Circulation: Cardiovascular Genetics</i> , 2016 , 9, 495-503		3
49	Lifestyle modification and weight reduction among low-income patients with the metabolic syndrome: the CHARMS randomized controlled trial. <i>Journal of Behavioral Medicine</i> , 2016 , 39, 483-92	3.6	11
48	Subfractions of High-Density Lipoprotein-Cholesterol and Carotid Intima-Media Thickness: The Northern Manhattan Study. <i>Stroke</i> , 2016 , 47, 1508-13	6.7	13
47	Elevated Lipoprotein Lipase Activity Does Not Account for the Association Between Adiponectin and HDL in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 2581-8	5.6	12
46	Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). <i>Diabetes</i> , 2015 , 64, 989-98	0.9	32
45	High HDL-C prevalence is common in type 1 diabetes and increases with age but is lower in Hispanic individuals. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 105-7	3.2	5
44	Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. <i>Diabetes Care</i> , 2014 , 37, 2622-31	14.6	76
43	Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. <i>Diabetes Care</i> , 2014 , 37, 2253-60	14.6	31
42	Clinical use of adiponectin as a marker of metabolic dysregulation. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014 , 28, 107-17	6.5	38

41	Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia. <i>Diabetes and Vascular Disease Research</i> , 2013 , 10, 256-62	3.3	7
40	Metabolic syndrome in andean populations. <i>Global Heart</i> , 2013 , 8, 349-354.e1	2.9	3
39	Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 318-24	4.9	11
38	Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 2077-90	9.4	38
37	Triglyceride response to an intensive lifestyle intervention is enhanced in carriers of the GCKR Pro446Leu polymorphism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, E1142-7	5.6	32
36	Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. <i>Endocrine Practice</i> , 2010 , 16, 617-28	3.2	31
35	Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia. <i>Diabetes Care</i> , 2010 , 33, 1021-4	14.6	14
34	Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. <i>Endocrine Practice</i> , 2010 , 16, 629-40	3.2	30
33	Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. <i>Diabetes Care</i> , 2009 , 32, 726-32	14.6	68
32	A new use for an old drug provides dual glucose and LDL-lowering therapy in the modern setting of T2D management: colesevelam HCL. <i>Current Diabetes Reports</i> , 2009 , 9, 331-2	5.6	
31	Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3171-82	5.6	460
30	10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. <i>Lancet, The</i> , 2009 , 374, 1677-86	40	2008
29	Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam - a clinical perspective. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2009 , 2, 11-21	3.4	2
28	Clinical decisions. Management of type 2 diabetes. <i>New England Journal of Medicine</i> , 2008 , 358, 293-7	59.2	29
27	Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes. <i>Journal of Clinical Lipidology</i> , 2008 , 2, 19-24	4.9	11
26	Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes. <i>Journal of Clinical Lipidology</i> , 2008 , 2, 25-35	4.9	8
25	Effects of niacin on glucose control in patients with dyslipidemia. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 470-8	6.4	83
24	Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. <i>Diabetes</i> , 2008 , 57, 980-6	0.9	135

23	Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. <i>Diabetes Care</i> , 2008 , 31, 811-22	14.6	439
22	Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. <i>Archives of Internal Medicine</i> , 2008 , 168, 1531-40		169
21	Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. <i>Archives of Internal Medicine</i> , 2008 , 168, 1975-83		179
20	Fish oil in the treatment of dyslipidemia. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2008 , 15, 167-74	4	26
19	Severe acquired (secondary) high-density lipoprotein deficiency. <i>Journal of Clinical Lipidology</i> , 2007 , 1, 41-56	4.9	20
18	Thiazolidinediones and vascular damage. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2007 , 14, 108-15	4	4
17	The forgotten bile acid sequestrants: is now a good time to remember?. <i>American Journal of Therapeutics</i> , 2007 , 14, 567-80	1	75
16	The new clinical trials with thiazolidinediones--DREAM, ADOPT, and CHICAGO: promises fulfilled?. <i>Current Opinion in Lipidology</i> , 2007 , 18, 435-42	4.4	14
15	Impact of thiazolidinediones on serum lipoprotein levels. <i>Current Atherosclerosis Reports</i> , 2006 , 8, 397-404		24
14	Thiazolidinediones : beyond glycemic control. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2006 , 5, 25-36		17
13	Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. <i>Mayo Clinic Proceedings</i> , 2006 , 81, 1579-88	6.4	100
12	Lifestyle interventions to prevent type 2 diabetes. <i>Lancet, The</i> , 2006 , 368, 1634-6	4.0	6
11	Management of dyslipidemia in diabetes. <i>Cardiology in Review</i> , 2006 , 14, 125-35	3.2	55
10	Lifestyle intervention to prevent diabetes: intensive and cost effective. <i>Current Opinion in Lipidology</i> , 2006 , 17, 37-44	4.4	37
9	Management of diabetic dyslipidemia. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005 , 34, 1-25, v	5.5	29
8	The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. <i>Annals of Internal Medicine</i> , 2005 , 142, 611-9	8	672
7	Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. <i>Diabetes Care</i> , 2005 , 28, 888-94	14.6	439
6	A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. <i>Diabetes Care</i> , 2005 , 28, 1547-54	14.6	664

5	Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. <i>Diabetes</i> , 2005 , 54, 1566-72	0.9	268
4	Cardiovascular disease in patients who have diabetes. <i>Cardiology Clinics</i> , 2003 , 21, 399-413, vii	2.5	26
3	Acquired HDL Deficiency Associated With Apolipoprotein A-I Reactive Monoclonal Immunoglobulins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002 , 22, 1740-1741	9.4	8
2	Circuit resistance training improves the atherogenic lipid profiles of persons with chronic paraplegia. <i>Journal of Spinal Cord Medicine</i> , 2001 , 24, 2-9	1.9	104
1	Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. <i>Circulation</i> , 1998 , 98, 2513-9	16.7	772